In the all-important Hospitals segment, Revenue in JH2017 was up 3.8% on pcp, but operating EBITDA was flat on JH2016.
I suspect the market will not be overly enamored with that outcome.
Valuations of 20x P/E and 12x EV/EBITDA probably require something more than static financial performance.
I have been wanting to buy HSO for some time, as I think it has some attractive long-term fundamentals.
But I've always thought it to be somewhat over-valued.
Looks like I might get my opportunity in the days/weeks ahead.
- Forums
- ASX - By Stock
- HSO
- Ann: FY17 Financial Report Media Release
Ann: FY17 Financial Report Media Release, page-2
-
- There are more pages in this discussion • 65 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)